News
AEP (AEP) Down 4.7% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for American Electric Power (AEP). Shares have lost about 4.7% in that time frame, underperforming the S&P 500.
But investors have to be wondering
Why Is ADM (ADM) Up 7.8% Since Last Earnings Report?
It has been about a month since the last earnings report for Archer Daniels Midland (ADM). Shares have added about 7.8% in that time frame, outperforming the S&P 500.
Will the recent positive trend
Broadcom Q2 Earnings Surpasses Estimates, Revenues Surge Y/Y
Broadcom AVGO reported second-quarter fiscal 2026 non-GAAP earnings of $2.44 per share, which beat the Zacks Consensus Estimate by 1.67% and rose 54% year over year. Revenues rose 48% year over year
PVH Q1 Earnings Top Estimates, FY26 Sales Outlook Cut, Stock Down
PVH Corporation PVH posted first-quarter fiscal 2026 results, wherein both earnings and revenues topped the Zacks Consensus Estimate. However, the bottom line fell year over year while the top line
Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development
Alnylam Pharmaceuticals ALNY has entered into a strategic collaboration with Inceptive Nucleics aimed at accelerating the discovery and development of next-generation RNA interference (RNAi)
OSIS Gains From Robust Demand, Faces Margin and Timing Headwinds
OSI Systems OSIS sits at an interesting crossroads. The company is working through a Mexico program transition, yet demand indicators remain strong and management expects cash collection to improve
CRWD Q1 Earnings Surpass Estimates on ARR Strength, AI Demand
CrowdStrike CRWD reported non-GAAP earnings per share of $1.10 for the first quarter of fiscal 2027, which surpassed the Zacks Consensus Estimate by 2.8%. The bottom line increased 50.7% on a
The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker
Key Points
- Interested in Amazon.com, Inc.? Here are five stocks we like better.
- A Blue Origin rocket explosion last week damaged the launchpad and set back Amazon's satellite rollout, sending the
PRU Expands Retirement Market Presence With Fixed Indexed Annuity
Prudential Financial, Inc. PRU is expanding its presence in the growing retirement market with the launch of Elevate. This new suite of fixed indexed annuities is aimed at strengthening Prudential's
Jobless Claims Increased More Than Expected
Pre-market futures are widely mixed at this hour, following a one-day purge yesterday from all-time highs the day before. Without making too much of this near-term jostling, we can acknowledge that
BFH Stock Trading at a Discount to Industry at 7.96X: Time to Buy?
Bread Financial Holdings, Inc. BFH shares are trading at a discount compared with the Zacks Financial - Miscellaneous Services industry. Its forward price-to-earnings multiple of 7.96X is lower than
Why High Oil Prices Won't Fully Derail VLO's Refining Strength
The Iran-war shock is driving the high crude oil prices, with the price of West Texas Intermediate (“WTI”) crude currently trading at more than the $90-per-barrel mark. The U.S. Energy Information
ONDS' Growing Active Opportunity Pipeline: Multi-Year Growth Secured?
Ondas Inc ONDS is witnessing a rapidly expanding opportunity pipeline. On the first-quarter 2026 earnings call, the company disclosed an active pipeline of approximately $4.3 billion in
CIEN Q2 Earnings Beat on AI-Led Networking Demand, FY26 View Elevated
Ciena Corporation CIEN reported fiscal second-quarter 2026 adjusted earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.46. The bottom line surged 290% year over year as
MP Gains 164% in a Year: Should You Buy, Sell or Hold the Stock?
MP Materials’ MP shares have skyrocketed 164.4% in the past year, significantly outperforming the industry’s 60.8% growth, the Zacks Basic Materials sector’s 49% rise and the S&P 500’s gain of 24%.
PVH Q1 Earnings Call Highlights
Key Points
- Interested in PVH Corp.? Here are five stocks we like better.
- PVH said it beat first-quarter expectations on EPS and operating margin, with revenue of $2 billion and continued
Columbus McKinnon Q4 Earnings Call Highlights
Key Points
- Interested in Columbus McKinnon Corporation? Here are five stocks we like better.
- Columbus McKinnon posted strong fiscal 2026 growth, with orders up 20%, net sales up 24% to a
ROP's Application Software Unit Keeps Growing: What's Next?
The Application Software segment remains the cornerstone of Roper Technologies, Inc.’s ROP growth strategy, delivering consistent expansion supported by healthy demand across its Aderant, Deltek
Are Humanoid Robots the Next Trillion-Dollar AI Theme? ETFs in Focus
The AI investment story may be entering a new chapter. While the first wave of artificial intelligence was driven by software, cloud computing and semiconductors, the next phase of AI's evolution
TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi
Shares of TG Therapeutics TGTX were up 9.5% yesterday after the company announced positive data from a phase I study evaluating the subcutaneous (“SC”) formulation of its sole marketed drug, Briumvi
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
Shares of Spyre Therapeutics SYRE were up 6.3% yesterday after the company announced that enrollment has been completed for all sub-studies in the SKYWAY basket study evaluating SPY072 (anti-TL1A)
Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
Key Points
- Interested in Starfighters Space, Inc.? Here are five stocks we like better.
- Weiss Ratings analyst Chris Graebe argues the largest IPO gains go to investors who enter companies at the
Key Reasons to Buy Atlassian Stock Despite 37% YTD Decline
Atlassian Corporation TEAM has seen a sharp fall in its stock price, declining 37.4% year to date (YTD), significantly underperforming the Zacks Computer and Technology sector’s growth of 23.5% and
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
ADC Therapeutics ADCT shares plunged 53.4% in after-hours trading on Wednesday despite the company reporting positive top-line results from a late-stage confirmatory study of Zynlonta in combination



